{
  "created_at": "Tue Jan 04 12:50:42 +0000 2022",
  "id_str": "1478044742885777410",
  "full_text": "“We believe that in 15 years, one-third of all newly approved drugs will be based on mRNA,” say the founders of @BioNTech_Group in The #WorldAhead 2022 https://t.co/REMyvvJ2dH",
  "display_text_range": [
    0,
    175
  ],
  "entities": {
    "hashtags": [
      {
        "text": "WorldAhead",
        "indices": [
          135,
          146
        ]
      }
    ],
    "symbols": [],
    "user_mentions": [
      {
        "screen_name": "BioNTech_Group",
        "name": "BioNTech SE",
        "id": 1060984350995550200,
        "id_str": "1060984350995550208",
        "indices": [
          112,
          127
        ]
      }
    ],
    "urls": [
      {
        "url": "https://t.co/REMyvvJ2dH",
        "expanded_url": "https://econ.st/3FcVMh7",
        "display_url": "econ.st/3FcVMh7",
        "indices": [
          152,
          175
        ]
      }
    ]
  },
  "user": {
    "name": "The Economist",
    "screen_name": "TheEconomist",
    "profile_image_url_https": "https://pbs.twimg.com/profile_images/879361767914262528/HdRauDM-_normal.jpg"
  },
  "retweet_count": 32,
  "favorite_count": 87,
  "possibly_sensitive": false,
  "original_created_at": "Mon Jan 03 16:45:02 +0000 2022",
  "localize": [
    {
      "locale": "ja",
      "full_text": "\"15年後には、新たに承認される医薬品の3分の1がmRNAに基づくものになると考えています。\" @BioNTech_Group の創業者は、The #WorldAhead 2022 https://t.co/REMyvvJ2dH で次のように述べています。"
    },
    {
      "locale": "zh",
      "full_text": "\"我们相信，15年后，所有新批准的药物中有三分之一将基于mRNA，\"@BioNTech_Group的创始人在#WorldAhead 2022 https://t.co/REMyvvJ2dH 中说。"
    },
    {
      "locale": "zh-Hant",
      "full_text": "\"我們相信，15年後，所有新批准的藥物中有三分之一將基於mRNA，\"@BioNTech_Group的創始人在#WorldAhead 2022 https://t.co/REMyvvJ2dH 中說。"
    }
  ]
}